<DOC>
	<DOCNO>NCT02293902</DOCNO>
	<brief_summary>Primary Objective : To demonstrate sarilumab added MTX reduce sign symptom rheumatoid arthritis ( RA ) Japanese RA patient inadequate response MTX . Secondary Objective : To assess safety sarilumab add MTX Japanese RA patient inadequate response MTX .</brief_summary>
	<brief_title>A Study Assessing Efficacy Safety Sarilumab Added MTX Japanese Patients With Moderately Severely Active Rheumatoid Arthritis ( SARIL-RA-KAKEHASI )</brief_title>
	<detailed_description>The total duration study expect 62 week ( screen period 4 week , treatment period 52 week , 6 week post treatment observation ) .</detailed_description>
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Folic Acid</mesh_term>
	<mesh_term>Vitamin B Complex</mesh_term>
	<criteria>Inclusion criterion : Diagnosis RA , accord American College Rheumatology/The European League Against Rheumatism ( ACR/EULAR ) 2010 Rheumatoid Arthritis Classification Criteria ≥3 month disease duration . Moderately severely active RA define : At least 8 68 tender joint 6 66 swollen joint screen visit . High sensitivity CReactive Protein ( hsCRP ) ≥6mg/L screen visit . Exclusion criterion : Patients &lt; 20 &gt; 75 year age . Treatment Diseasemodifying antirheumatic drug ( DMARD ) MTX biologic agent without appropriate offdrug period prior screen . Prior treatment antiinterleukin6 ( antiIL6 ) antiinterleukin6 receptor ( IL6R ) antagonist therapy , include limited tocilizumab sarilumab . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>